Tofacitinib for Calcinosis Cutis Associated With Juvenile Dermatomyositis: An Open-Label Single-Arm Study

Area of Science:

• Rheumatology
• Pediatrics
• Dermatology

Background:

• Calcinosis cutis (CC) is a common complication in juvenile dermatomyositis (JDM), often resistant to standard treatments.
• Type I interferon (IFN) pathway dysregulation is implicated in CC pathogenesis.
• JAK inhibitors, like tofacitinib, may modulate this pathway and offer therapeutic benefits.

Purpose of the Study:

• To evaluate the efficacy of tofacitinib in reducing the burden of CC in pediatric JDM patients.
• To assess the safety and tolerability of tofacitinib in this population.

Main Methods:

• Open-label, single-arm study involving children (2-18 years) with JDM and CC.
• Tofacitinib was administered orally alongside standard JDM therapies.
• Primary endpoint: change in Agatston score (CT scan) at 24 weeks; secondary endpoints included clinical scores and IFN levels.

Main Results:

• Twenty children completed the study; 18 had JDM with CC, 2 had JDM-systemic sclerosis overlap.
• Significant reduction in median Agatston score from baseline to follow-up (P=0.012).
• No serious adverse events were reported during the study period.

Conclusions:

• Tofacitinib, as an add-on therapy, effectively reduced CC burden in children with JDM.
• The treatment demonstrated a favorable safety profile in the study population.
• Tofacitinib represents a promising therapeutic option for managing CC in JDM.